Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Harrington, KJ; Billingham, LJ; Brunner, TB; Burnet, NG; Chan, CS; Hoskin, P; Mackay, RI; Maughan, TS; Macdougall, J; McKenna, WG; Nutting, CM; Oliver, A; Plummer, R; Stratford, IJ; Illidge, T.
Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers.
Br J Cancer. 2011; 105(5):628-39
Doi: 10.1038/bjc.2011.240
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Brunner Thomas Baptist
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- There is a growing appreciation of the potential value of combining novel molecularly-targeted drugs with radiotherapy or chemoradiotherapy. Such approaches have the potential to improve locoregional disease control and cure rates across a diverse range of tumour types. In this report, we outline a rational framework for developing novel drug-radiation combinations. In doing so, we make recommendations regarding the core preclinical data sets that are required to serve as justification for studies in humans and describe potential clinical trial designs that may be adopted by investigators.
- Find related publications in this database (using NLM MeSH Indexing)
- Algorithms - administration & dosage
- Clinical Trials as Topic - methods, standards
- Drug Evaluation, Preclinical - standards
- Drugs, Investigational - pharmacology, therapeutic use
- Humans - administration & dosage
- Models, Biological - administration & dosage
- Neoplasms - radiotherapy
- Practice Guidelines as Topic - administration & dosage
- Radiation-Sensitizing Agents - pharmacology, therapeutic use
- Find related publications in this database (Keywords)
- assessment
- novel radiosensitisers
- early
- preclinical
- clinical